Companies /Healthcare

Prestige Consumer Healthcare Inc

NYSE: PBH Drug Manufacturers - Specialty & Generic
$50.62
▲ $2.40 (+4.98%) today
Markets closed · 11:10pm ET

24/7 Wall St. View

PBH at a Glance

Valuation
Market cap
$2.3B
P/E ratio
14.9
Profitability
Revenue (TTM)
$1.2B
Profit margin
13.3%
EPS (TTM)
$3.24
Price
52-week range
$42 – $71
24/7 target
$67.23
Street target
$66.20
Earnings
Next report
Feb 3, 2027

Headquartered in Tarrytown, NY Fiscal year ends March NYSE: PBH prestigebrands.com

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc. (NYSE: PBH) markets, sells, manufactures and distributes over-the-counter (OTC) healthcare and personal care products.

It operates in the U.S., Canada, Australia and select other international markets. It reports two segments: North American OTC Healthcare and International OTC Healthcare.

Its portfolio of needs-based consumer health brands spans several categories:
- **Eye care:** Clear Eyes, TheraTears
- **Women's health:** Monistat, Summer's Eve
- **Analgesics:** BC, Goody's
- **Motion sickness:** Dramamine
- **GI and digestive:** Fleet, Gaviscon
- **Oral care:** DenTek
- **Skin care:** Compound W, Dermal Therapy, Flexitol, Boudreaux's Butt Paste
- **Cough/cold:** Chloraseptic, Luden's, Little Remedies
- **Rehydration:** Hydralyte
- **Other:** Nix lice treatment, Debrox ear care

The company has recently expanded through acquisitions:
- **Breathe Right nasal strips** (closed June 2026), focused on nighttime breathing.
- **LaCorium Health** (closed July 1, 2026), an Australian skin care business behind Dermal Therapy and Flexitol.
- **Pillar5**, an eye care manufacturing facility that vertically integrates its Clear Eyes supply chain. The plant is currently under remediation, with constrained production.

The company sells through retail and growing eCommerce channels. It relies on brand-building advertising and a high free-cash-flow model, and is currently focused on reducing roughly $2 billion of net debt. Updated

Latest Activity

PBHPrestige Consumer Healthcare
Q2 2027
EPS
$1.13
est $1.07+5.8%
Revenue
$336M
est $329M+2.2%

Management cut full-year adjusted EPS guidance to $4.48 to $4.55 from $4.55 to $4.65, blaming Clear Eyes production problems at the newly acquired Pillar5 plant that will limit supply all second half. The double beat came entirely from acquisitions, with organic revenue down 1.6%.

Quarterly EPS — reported vs estimate

PBH Coverage

3:01pm ET
Investing

52-Week Low Club (December 28, 2007)

Some of these stocks hit 52-week lows and recovered off of lows so they won’t have a low close.  But these did all touch or breach the 52-week lows.  At the end…

Douglas A. McIntyre

Frequently Asked Questions

What does Prestige Consumer Healthcare do?

Prestige Consumer Healthcare Inc. (NYSE: PBH) markets, sells, manufactures and distributes over-the-counter (OTC) healthcare and personal care products. It operates in the U.S., Canada, Australia and select other international markets.

What is the PBH stock price target?

24/7 Wall St.'s 12-month price target for PBH is $67.23, rated Buy. The Wall Street consensus target is $66.20. PBH price prediction →